the results of comparative analysis of angiogenic and laser therapy for diabetic macular edema in diabetes type 2

Clicks: 287
ID: 183182
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #12 of 43 articles by views in Neuro-Oncology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract

Purpose: To compare the results of laser treatment and intravitreal ranibizumab injections in patients with DME consistent with the level of VEGF A in tear fluid.


Methods: The progress of visual acuity, retinal thickness and light sensivity after laser treatment and ranibizumab intravitreal injection has been assessed.


Results: One month after the treatment the main effect of laser was the decrease of retinal thickness, whereas after ranibizumab — the increase of visual acuity. The significant decrease of VEGF A level in tear fluid was found only in ranibizumab group.


Conclusion: Laser treatment of DME leads to permanent retinal thickness decrease and insignificant functional improvement in comparison with ranibizumab IV injection, which leads to temporary morphological and functional improvement.

Reference Key
vorobieva2014oftalmologithe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;I. V. Vorobieva;E. V. Parfenova;D. A. Merkushenkova;P. I. Makarevich;V. I. Alekhnovich
Journal Neuro-Oncology
Year 2014
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.